Aytu BioPharma (NASDAQ:AYTU) Price Target Raised to $14.50

Aytu BioPharma (NASDAQ:AYTU) had its target price upped by research analysts at Ascendiant Capital Markets from $14.00 to $14.50 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other research firms also recently commented on AYTU. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Wednesday, April 8th. Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Aytu BioPharma currently has a consensus rating of “Hold” and a consensus target price of $9.83.

Aytu BioPharma Stock Down 2.6%

NASDAQ:AYTU opened at $2.24 on Thursday. The firm’s 50 day simple moving average is $2.41 and its 200 day simple moving average is $2.45. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.12 and a quick ratio of 1.00. Aytu BioPharma has a one year low of $1.65 and a one year high of $3.07. The company has a market cap of $24.04 million, a PE ratio of -0.49 and a beta of 0.24.

Aytu BioPharma (NASDAQ:AYTU) last posted its earnings results on Wednesday, May 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%.The business had revenue of $12.41 million for the quarter, compared to analyst estimates of $12.05 million. On average, research analysts anticipate that Aytu BioPharma will post -0.69 earnings per share for the current year.

Institutional Trading of Aytu BioPharma

Hedge funds have recently modified their holdings of the stock. Daytona Street Capital LLC bought a new stake in shares of Aytu BioPharma in the 4th quarter valued at $26,000. Rothschild Wealth LLC bought a new stake in Aytu BioPharma during the 4th quarter valued at $52,000. Bellevue Asset Management LLC purchased a new position in Aytu BioPharma during the 4th quarter worth $65,000. XTX Topco Ltd purchased a new position in Aytu BioPharma during the 4th quarter worth $67,000. Finally, DRW Securities LLC purchased a new position in Aytu BioPharma during the 4th quarter worth $76,000. Institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.